Undisclosed ROR1 ADC
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 25, 2023
Chinese researchers patent new ROR1-targeting antibody-drug conjugates for cancer
(Bioworld)
- "Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceuticals Co. Ltd. have disclosed antibody-drug conjugates (ADC) comprising human monoclonal antibodies targeting ROR1 covalently linked to exatecan through a linker. They are reported to be useful for the treatment of cancer."
Patent • Oncology
1 to 1
Of
1
Go to page
1